Jacobson Pharma Issues Positive Profit Alert

Expects to Record Over 20% Increase in Profit Attributable to Shareholders

�

HONG KONG, CHINA – Media OutReach – 2 May 2019 - Jacobson Pharma Corporation Limited (“Jacobson Pharma“ or the  “Company”; Stock Code: 2633), a leading company
engaging in the research, development, production, marketing and sale of
generic drugs and proprietary medicines, has today announced
a positive profit alert. Based on a preliminary review
on the unaudited consolidated management accounts of the Group for the
financial year ended 31 March 2019, the Group is expected to record an increase
of over 20% in the consolidated profit attributable to shareholders of the Company
as compared with that for the financial year ended 31 March 2018.

 

The encouraging results were mainly attributable
to a steady growth of generic drug business along with the sales revenue
generated from newly in-licensed products coupled with an uplifted sales
performance on proprietary medicines. Operating
leverages and financial savings
derived from cost control measures, as well as fair value gain on investment
properties of the Group are also expected to contribute to the above-mentioned
increase.

 

Embedding
the strategies of regional expansion and targeted portfolio enhancement through
in-licensing or products developed in-house, Jacobson Pharma aims to become a
leading generic drug and proprietary medicine company in Asia by building a
commercially competitive platform in the region.

 

Backed by a vertically-integrated supply
chain and its efficient
production facilities as well as a robust in-house research and development pipeline, the Group is among the few with the most
extensive sales and distribution coverage in both the private and public sectors in Hong Kong and is poised for a
broadened geographic footprint.

 

Mr. Derek
Sum, Chairman and Chief Executive Officer of Jacobson Pharma, said, “The
expected increase in earnings of the Company reflects the effectiveness of our
across-the-board efforts and demonstrates our capabilities to execute on our
growth strategies. From expanding our product portfolios to optimizing the  operating leverage across our production facilities as well
as  implementing effective cost controls, our
holistic and prudent approach is aimed at facilitating the Group’s long-term
growth and creating value for our shareholders.”

About Jacobson Pharma Corporation Limited (????????????Stock Code: 2633)

Jacobson Pharma is the largest generic drug company in
Hong Kong with over 30% share of the total generic drug market for each year
since 2012. The Group’s proprietary medicines, notably being Po Chai Pills (?????), Tong Tai Chung Woodlok Oil (????????), Ho
Chai Kung Tji Thung San (??????????), Contractubex Scar Gel (???????) Doan’s Ointment (???????), Flying Eagle Wood Lok Medicated Oil (???????), Saplingtan (?????), Shiling Oil (?????) and Col-gan Tablet (?????) have been widely recognized by
the market. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap
Index since 1 June 2017. For more details about Jacobson Pharma, please visit
the Group’s website: http://www.jacobsonpharma.com